NumFin

Hubei Biocause Pharmaceutical Co., Ltd.

Simbolis: 000627.SZ

SHZ

2.3

CNY

Rinkos kaina šiandien

  • -19.6629

    P/E santykis

  • 0.1626

    PEG koeficientas

  • 11.27B

    MRK kapitalizacija

  • 0.05%

    DIV pajamingumas

Hubei Biocause Pharmaceutical Co., Ltd. (000627-SZ) Finansinės ataskaitos

Download
MetinisKetvirtinis
LinijinisLoginis
Diagramoje matote numatytuosius skaičius dinamikoje Hubei Biocause Pharmaceutical Co., Ltd. (000627.SZ). Įmonės pajamos rodo NaN M vidurkį, kuris yra NaN % gowth. Vidutinis viso laikotarpio bendrasis pelnas yra NaN M, kuris yra NaN %. Vidutinis bendrojo pelno rodiklis yra NaN %. Įmonės praėjusių metų veiklos grynojo pelno augimas yra NaN %, kuris lygus NaN % % vidutiniškai per visą bendrovės istoriją.,

MetinisKetvirtinis
10Y20Y30Y40Y

Balansas

Pasinerdami į Hubei Biocause Pharmaceutical Co., Ltd. fiskalinę trajektoriją, stebime vidutinį turto augimą. Įdomu tai, kad šis rodiklis yra , atspindintis tiek aukščiausias, tiek žemiausias įmonės rodiklius. Palyginus per ketvirtį, šis skaičius pakoreguojamas iki . Žvilgtelėjus į praėjusius metus, matyti, kad bendras turto pokytis yra NaN. Akcininkų vertė, kurią parodo bendras akcininkų nuosavas kapitalas, vertinama pagal NaN ataskaitine valiuta. Šio aspekto pokytis per metus yra NaN%.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996199519941993

balance-sheet.row.cash-and-short-term-investments

02995228391.826157.8
30248.8
15203.5
18317.5
15336.9
10953.2
61.6
58.9
124.3
152.8
74.1
72.9
95.1
306.7
111.3
73.5
26.9
16.8
55.5
73.7
247
104.9
74.6
96
104.9
113.5
13.9
13.9
13.6

balance-sheet.row.short-term-investments

01798.42082.52907.5
3391.6
2211.8
62842.7
4164.8
50767.4
418.6
0
0
0
0
0
0
16.1
3.2
1.3
0
0
0
1.4
0
0
0
0
12
0
13.5
13.5
13.5

balance-sheet.row.net-receivables

00-28453.617772.1
15069.6
10639.8
45548.8
9204.3
7697.9
83.7
140.8
188.6
339.1
391
277
295.6
231
198.2
318.7
428
407.2
455.9
280.7
296.1
28.7
8.7
8
4.1
5.6
3.4
0.2
26

balance-sheet.row.inventory

04131.91050410224.5
10716.2
3671.6
3820.5
569.4
438.5
136.1
140.4
133.9
134.4
150.2
194.2
273.9
259.2
200.4
156.1
135
128.6
125.8
129.8
90.7
70.6
75.6
66.7
16.1
30
18.4
5.3
1.4

balance-sheet.row.other-current-assets

0045535.3-3796
-4291.5
-3729.8
-17868.2
2283.9
645.2
57.7
53.8
-8.1
-98.7
-45.5
-33.6
-29.1
-26.9
0.1
-93.8
-146.6
-130.9
-169.3
0
-105.7
171.7
92.1
73.9
23.9
18.1
23.2
19
-12.8

balance-sheet.row.total-current-assets

050665.955977.650358.4
51743.1
25785
49818.6
27394.5
19734.9
339.2
394
438.7
527.6
569.9
510.5
635.5
770
510
454.5
443.3
421.7
467.9
484.2
528.1
375.9
251.1
244.7
149
167.2
58.9
38.3
28.2

balance-sheet.row.property-plant-equipment-net

01290.6844.1830.3
580.4
567.2
770.9
698.9
587.4
334.7
454.2
619.2
601.7
448.9
527
798.5
612.4
374.3
354.7
336.6
343.3
338.4
322.2
262.9
355.1
376.4
274.9
159.7
111.5
63
32.9
26.5

balance-sheet.row.goodwill

06192.56192.26192.2
6192.2
6186.3
6186.3
6186.3
6186.3
0
0
0
0
0
1.8
1.8
1.8
1.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

0283.2299.3269.7
190
109.4
213.4
519.9
549.1
490.4
503.9
363.5
374.7
382.8
410.6
363.6
316.5
261.9
257.6
179.6
186.8
189.1
184.4
123.5
105
109.3
16.4
16.8
16.3
10.8
3.8
3.9

balance-sheet.row.goodwill-and-intangible-assets

06475.76491.66461.9
6382.2
6295.7
6399.7
6706.2
6735.4
490.4
503.9
363.5
374.7
382.8
412.3
365.4
318.3
263.7
257.6
179.6
186.8
189.1
184.4
123.5
105
109.3
16.4
16.8
16.3
10.8
3.8
3.9

balance-sheet.row.long-term-investments

0133897.1129743.213020.4
12217.8
12396.1
12983.8
15056.2
8280.1
742
716.8
689.8
543.4
463.3
517.5
330.1
260.4
172.5
100.1
127
127.3
94
100.6
74.4
43.9
22.5
139.1
12
0
13.5
13.5
13.5

balance-sheet.row.tax-assets

026542280.31010.3
976.2
944.2
1189.4
39.5
69.8
69.3
30.5
45.7
17.3
18.7
8.9
9.1
7.6
4.7
-2.7
-127
-127.3
-94
-2.7
0
1.8
1.9
2.3
-12
0
-13.5
-13.5
-13.5

balance-sheet.row.other-non-current-assets

0106952.593262192222.6
167502.9
159285.8
107091.6
90521.3
82469.2
433.6
9.1
0
0
0
0
17.2
10.9
-0.7
3.2
128.4
129.5
95.6
1.7
0.2
4.6
9.4
5
44.3
35.9
1.7
3.1
1.4

balance-sheet.row.total-non-current-assets

0251270232621.1213545.5
187659.6
179488.9
128435.4
113022.2
98141.8
2070.1
1714.5
1718.3
1537.1
1313.7
1465.8
1520.3
1209.6
814.6
712.9
644.6
659.6
623.1
606.2
461
510.4
519.5
437.8
220.8
163.8
75.5
39.8
31.8

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

0301935.9288598.7263904
239402.6
205273.9
178254
140416.7
117876.7
2409.2
2108.5
2157
2064.7
1883.6
1976.3
2155.7
1979.5
1324.5
1167.4
1087.9
1081.3
1091
1090.4
989.1
886.3
770.7
682.5
369.8
331
134.4
78.2
60.1

balance-sheet.row.account-payables

0949206.993.5
35
156.5
83.5
106.1
82.8
74.4
112.8
208.7
84.8
62.6
34.8
37.5
45
67.9
119.6
45.7
51
25.7
26.8
18.6
51.6
29.5
40.1
19
12.5
7.5
3.1
0

balance-sheet.row.short-term-debt

018248.121189.69425.8
4583.8
6179.8
4640
7732.3
1414
303.5
428.9
484.6
327.8
253.2
142.8
274.8
192.7
279.4
231.9
252.4
251.4
284.4
249.4
134.5
154.4
96.4
54.9
7.7
14.9
8.1
3.3
6

balance-sheet.row.tax-payables

078.585.1142.5
65.4
223.8
338.4
19.2
53.3
2.1
3.7
-43.3
-48.5
-9.7
0.6
6.9
2.8
29.3
11.2
3.6
2.4
6.6
9.7
32
26.4
15.4
6.2
6.6
15.1
8.8
10.5
2.2

balance-sheet.row.long-term-debt-total

07170.86877.96203.6
2760.3
-69.4
110.5
40.5
360
42
0
0
23
123
123
225
160
30
30
0
0
0
0
0
9
14
14
58.4
56.8
24.4
2.7
5.8

Deferred Revenue Non Current

0179576.7241.8154781.7
147076.1
69.4
10.9
15.3
16
17.6
19.4
0
0
0
0
0
-160
-30
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

0463347.4258.5
52
69.4
21424.5
8957.1
2072
8.3
8.8
14.5
12.6
5.9
13.1
20.5
11.8
17.6
21.7
23.7
22.7
19.3
16.8
8.2
12.8
5.3
4.9
0.8
6.4
1.5
0.8
6.9

balance-sheet.row.total-non-current-liabilities

0243840.1229010213369.4
196798.4
162486.6
125753.1
103441.9
93669.4
198.5
41.3
15.8
34.8
134.5
134.5
225
160.2
30
30
0
0
0
0
0
9
16.2
15.2
58.4
56.8
24.4
2.7
5.8

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

071.689.6111.2
69.3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

0268302.2253995.8226429.3
204814.7
170920.5
152239.5
113711.8
97479.2
625.5
618.8
720.7
527.4
469.5
374.2
581.3
466.8
458.5
443.7
356.7
357.4
372.2
322.4
226.1
291.8
199
189.5
176.6
130.9
82
34.3
18.8

balance-sheet.row.preferred-stock

001085.90
763.7
595.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

04940.64940.64940.6
4940.6
4940.6
4940.6
4940.6
4259.2
1353.6
1353.6
1353.6
1353.6
1353.6
1353.6
676.8
676.8
594.8
594.8
594.8
594.8
594.8
594.8
517.2
278.9
232.4
129.1
103.2
103.2
40.5
40.5
40.5

balance-sheet.row.retained-earnings

053106508.56327.4
5909.4
5829
4247.5
3142.4
1922.7
184.6
-37
-171.9
-70.8
-82.7
19
104.6
58.6
106.1
13.1
-31.5
-37.4
-41.7
6.4
27.8
73.4
59.9
36.2
12
32.9
3.4
0
0.8

balance-sheet.row.accumulated-other-comprehensive-income-loss

00-1085.9236.6
-763.7
-595.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

010339.49962.811048.6
10284.9
10453.5
9804
11254
7619.9
201.5
132.4
214.1
214.7
105.3
172.4
736.8
726.2
113.6
99.1
94.7
93.5
92.8
92.8
143.6
175.4
215.1
312.4
77.9
64
8.5
3.3
0

balance-sheet.row.total-stockholders-equity

020590.12141222553.3
21134.9
21223.1
18992.1
19337
13801.8
1739.7
1449
1395.8
1497.5
1376.2
1545
1518.2
1461.6
814.5
707
658
650.9
645.9
694
688.7
527.7
507.4
477.7
193.2
200.1
52.4
43.9
41.3

balance-sheet.row.total-liabilities-and-stockholders-equity

0301935.9288598.7263904
239402.6
205273.9
178254
140416.7
117876.7
2409.2
2108.5
2157
2064.7
1883.6
1976.3
2155.7
1979.5
1324.5
1167.4
1087.9
1081.3
1091
1090.4
989.1
886.3
770.7
682.5
369.8
331
134.4
78.2
60.1

balance-sheet.row.minority-interest

013043.71319114921.3
13453
13130.4
7022.5
7367.8
6595.7
44
40.7
40.4
39.9
37.9
57
56.3
51.2
51.6
16.7
73.2
73
72.9
74.1
74.3
66.8
64.2
15.3
0
0
0
0
0

balance-sheet.row.total-equity

033633.834602.937474.7
34587.9
34353.5
26014.5
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

0135695.6131825.7116261.7
119224.9
120538.2
75826.6
61072.9
59047.4
1160.6
716.8
689.8
543.4
463.3
517.5
330.1
244.3
169.3
98.7
127
127.3
94
99.2
74.4
43.9
22.5
139.1
24
0
27
27
27

balance-sheet.row.total-debt

025418.928067.59425.8
4583.8
6179.8
4640
7732.3
1414
303.5
428.9
484.6
327.8
253.2
142.8
274.8
192.7
279.4
231.9
252.4
251.4
284.4
249.4
134.5
154.4
96.4
54.9
7.7
14.9
8.1
3.3
6

balance-sheet.row.net-debt

0-2734.71758.2-13824.5
-22273.3
-6811.9
-13677.5
-3439.9
-9539.2
241.9
370
360.3
175
179.1
69.9
179.7
-97.9
171.4
159.7
225.5
234.6
228.9
177.1
-112.5
49.6
21.7
-41.1
-85.2
-98.7
7.7
2.9
5.9

Pinigų srautų ataskaita

Hubei Biocause Pharmaceutical Co., Ltd. finansiniame kraštovaizdyje per pastarąjį laikotarpį pastebimas pastebimas laisvųjų pinigų srauto pokytis, rodantis NaN pokytį. Bendrovė neseniai išplėtė savo akcinį kapitalą išleisdama NaN, o tai rodo NaN skirtumą, palyginti su praėjusiais metais. Bendrovės investicinė veikla lėmė grynųjų pinigų panaudojimą, kuris ataskaitine valiuta sudarė NaN. Tai NaN pokytis, palyginti su praėjusiais metais. Tuo pačiu laikotarpiu bendrovė užregistravo NaN, NaN ir NaN, kurie yra svarbūs norint suprasti įmonės investavimo ir grąžinimo strategijas. Bendrovės finansinė veikla lėmė grynųjų pinigų panaudojimą NaN, o per metus skirtumas buvo NaN. Be to, bendrovė skyrė NaN dividendams akcininkams išmokėti. Kartu ji ėmėsi kitų finansinių manevrų, vadinamų NaN, kurie taip pat turėjo didelės įtakos jos pinigų srautams šiuo laikotarpiu. Šie komponentai kartu sudaro išsamų įmonės finansinės būklės ir strateginio požiūrio į pinigų srautų valdymą vaizdą.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998

cash-flows.row.net-income

0510.6880.21117.9
2918.6
2377.3
2678.3
3108.8
250.5
84.1
-100.4
13.8
-107.2
29.1
55.3
17.1
101.6
53.1
8.1
4.9
-49
7.8
46.7
40.3
35.4
30.5

cash-flows.row.depreciation-and-amortization

0147.3133.963.7
79.2
1123.9
122.9
139.3
64.8
73.5
68.8
52.4
62.9
66.5
52.3
40.5
42
35.6
37.6
35.9
34.2
37.3
28.9
28.6
25.1
13.1

cash-flows.row.deferred-income-tax

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

016073.111933.530709.3
35361
-26789.8
5245.9
-6232.5
23.9
-78.9
116.7
78
51.7
149.3
-122.8
-96.1
27.3
51.8
-13.7
15
-22.3
-131.2
-41.5
-83.5
-23.6
-52.1

cash-flows.row.account-receivables

01642.4-609.1-279.5
1548.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

0-279.6471.1-188.3
177.6
120.5
-130.9
-302.4
1.7
-6.5
0.5
15.8
12.3
79.7
-14.7
-58.7
-44.4
-21
-6.4
-1.8
4
-37.2
-20.1
4.9
8.9
-29

cash-flows.row.account-payables

0-1642.4609.1279.5
-1548.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

016352.611462.530897.6
35183.5
-26910.3
5376.7
-5930.1
22.2
-72.4
116.2
62.2
39.5
69.6
-108.1
-37.3
71.6
72.9
-7.3
16.8
-26.3
-94
-21.4
-88.4
-32.5
-23.1

cash-flows.row.other-non-cash-items

0-9206.7-8775.1-10469.8
-9759.2
38269.9
-7615.5
642
-385.9
-200
45.4
-50.4
59.5
-20.2
-5.3
24.9
-52.3
-12.4
16.7
0.3
11.2
16.5
3.2
10
10
3.4

cash-flows.row.net-cash-provided-by-operating-activities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

0-135.1-287.1-308.4
-717.1
-274.7
-778.9
-3678.3
-40.8
-185.5
-143.8
-128.5
-149.4
-93.1
-261.7
-361.7
-64.8
-130.1
-24.5
-25.5
-21.5
-146.1
-31.5
-6.3
-99.2
-10.8

cash-flows.row.acquisitions-net

0171.8-3440.5
258.8
334.3
1.4
3.5
3.2
103.1
162.9
131
44.3
0
263.4
361.8
65.9
130.1
0
28.3
21.8
146.9
0.2
10.7
0
10.8

cash-flows.row.purchases-of-investments

0-97626.8-109755-71494.6
-123082.8
-77372.7
-139091.6
-115403.5
-6.2
-230
-146.7
-60
-40
-120.1
-40
-189
-60
-55.6
-0.8
-39
-165.8
-184.7
-24.8
-20.2
0
-31.5

cash-flows.row.sales-maturities-of-investments

084126.194717.767783.5
88942.6
68035
129051.5
104526.6
182.1
464.4
89
130
170
0
17.8
92.7
43.2
26.7
0
15.6
175.7
129.6
1.1
12.2
29.9
12

cash-flows.row.other-investing-activites

0-1996.2-62.2-222.2
-445.9
102.8
-47.8
17138.3
7.1
5.3
-143.8
-128.5
-149.4
207.6
-261.7
-361.7
-64.8
-130.1
0
-25.5
-21.5
-146.1
62
-6.3
0.5
-10.8

cash-flows.row.net-cash-used-for-investing-activites

0-15615-15384.8-7682.2
-35044.3
-9175.3
-10865.4
2586.6
145.4
157.2
-182.4
-56
-124.4
-5.6
-282.2
-458
-80.4
-159
-25.3
-46.2
-11.3
-200.6
7
-9.9
-68.8
-30.3

cash-flows.row.debt-repayment

0-11763.8-7701.9-854.1
-102.8
-288
-790
-447.5
-464.9
-573.5
-463.3
-294.8
-223.3
-594.8
-279.7
-413.2
-231.9
-255.8
-240.6
-235.4
-329.9
-345.9
-178.9
-59.8
-67.9
-17.2

cash-flows.row.common-stock-issued

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-repurchased

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

0-699.4-381.3-634
-242.1
-311.6
-148
-117.1
-24.5
-30.6
-30.4
-28.7
-21.6
-37.3
-20
-52.4
-17.8
-12.3
-14.3
-15.5
-15
-16.1
-22.7
-15.1
-6.2
-58.7

cash-flows.row.other-financing-activites

02354115703.91660.6
1470.2
1940.4
11597.1
11190.3
407
515.3
484.6
364.4
303.7
390.8
406.8
1119.6
247.4
344.2
241.6
202.4
364.9
457.5
299.4
119.6
74.8
114.5

cash-flows.row.net-cash-used-provided-by-financing-activities

011077.87620.6172.6
1125.3
1340.8
10659.2
10625.7
-82.4
-88.8
-9.1
40.9
58.8
-241.3
107.2
654.1
-2.3
76.2
-13.3
-48.6
20
95.5
97.8
44.7
0.6
38.6

cash-flows.row.effect-of-forex-changes-on-cash

072-15.2-33.9
-1.4
1.6
-2.1
3.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-0.1
0

cash-flows.row.net-change-in-cash

03059-3606.913877.6
-5320.8
7148.4
223.2
10873.7
16.2
-52.8
-61.1
78.7
1.3
-22.2
-195.5
182.6
35.8
45.3
10
-38.7
-16.8
-174.7
142.2
30.2
-21.4
3.1

cash-flows.row.cash-at-end-of-period

026309.323250.326857.1
12979.5
18300.4
11152
10928.8
55.1
38.9
91.8
152.8
74.1
72.9
95.1
290.6
108
72.2
26.9
16.8
55.5
72.3
247
104.9
74.6
96

cash-flows.row.cash-at-beginning-of-period

023250.326857.112979.5
18300.4
11152
10928.8
55.1
38.9
91.8
152.8
74.1
72.9
95.1
290.6
108
72.2
26.9
16.8
55.5
72.3
247
104.9
74.6
96
92.9

cash-flows.row.operating-cash-flow

07524.24172.621421.1
28599.6
14981.3
431.6
-2342.3
-46.7
-121.3
130.5
93.8
66.9
224.6
-20.5
-13.5
118.6
128.2
48.7
56.1
-25.9
-69.6
37.3
-4.6
46.9
-5.2

cash-flows.row.capital-expenditure

0-135.1-287.1-308.4
-717.1
-274.7
-778.9
-3678.3
-40.8
-185.5
-143.8
-128.5
-149.4
-93.1
-261.7
-361.7
-64.8
-130.1
-24.5
-25.5
-21.5
-146.1
-31.5
-6.3
-99.2
-10.8

cash-flows.row.free-cash-flow

07389.13885.521112.7
27882.5
14706.7
-347.4
-6020.6
-87.5
-306.8
-13.3
-34.7
-82.4
131.5
-282.2
-375.2
53.8
-1.9
24.1
30.5
-47.4
-215.8
5.8
-10.9
-52.3
-16

Pajamų ataskaitos eilutė

Hubei Biocause Pharmaceutical Co., Ltd. pajamos, palyginti su ankstesniu laikotarpiu, pasikeitė NaN%. Pranešama, kad bendrasis 000627.SZ pelnas yra NaN. Bendrovės veiklos sąnaudos yra NaN, palyginti su praėjusiais metais, jos pakito NaN%. Nusidėvėjimo ir amortizacijos sąnaudos yra NaN, o tai yra NaN% pokytis nuo praėjusio ataskaitinio laikotarpio. Pranešama, kad veiklos išlaidos yra NaN, kurios rodo NaN% pokytį per metus. Pardavimo ir rinkodaros išlaidos yra NaN, kuris yra NaN% рokytis, palyginti su praėjusiais metais. Naujausiais duomenimis pagrįsta EBITDA yra NaN, o tai reiškia NaN% augimą per metus. Veiklos pajamos yra NaN, kurios rodo NaN% pokytį, palyginti su praėjusiais metais. Grynųjų pajamų pokytis yra NaN%. Praėjusių metų grynosios pajamos buvo NaN.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995

income-statement-row.row.total-revenue

049725.849615.749583.2
43576
50192.1
30950.8
53405.6
16995.5
541.1
806.4
968
779.7
1133.8
1261.2
964.6
909.3
835.8
560.8
518.7
463
422.7
348.6
356
322
255.9
192.3
237.5
143.7
83.3

income-statement-row.row.cost-of-revenue

09829.68458.67311.6
3225.1
8172.6
2866.9
4036.6
1788.5
518
829.8
977.5
753.2
1111.8
1185.8
866.2
835.1
726.1
475.6
451.1
410.6
380.8
268.7
261.2
240.2
193
155.3
176.4
98.2
53.9

income-statement-row.row.gross-profit

039896.241157.142271.6
40350.8
42019.5
28083.9
49368.9
15207
23.1
-23.4
-9.6
26.5
22
75.3
98.4
74.2
109.7
85.1
67.7
52.5
41.8
79.9
94.9
81.8
62.8
37
61.2
45.6
29.3

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

0-48509.69825.59896.8
36146.5
30062.1
-24280.3
-23688.3
-6190.4
3.1
8.3
13.2
1.5
0.3
9.8
6
5
6
10.3
4.7
9.5
1.5
2.6
8.3
7.3
20.6
11.9
5.6
6.6
2

income-statement-row.row.operating-expenses

0-48509.610159.510437.9
36774.7
30668.5
2614.7
26761
6911.4
79.6
70.9
73.6
63.9
80.2
67.9
52.8
59
55.4
45.9
49.3
50.8
83.4
57
45
36.6
36.2
13
10
10.3
6.8

income-statement-row.row.cost-and-expenses

0-51566.718618.117749.5
39999.8
38841.1
5481.6
30797.6
8699.9
597.6
900.7
1051.1
817.1
1192
1253.7
919
894.1
781.4
521.5
500.4
461.3
464.2
325.6
306.1
276.7
229.2
168.3
186.3
108.5
60.7

income-statement-row.row.interest-income

0000
0
0
0
16.1
0
2.3
2.6
1.5
2.2
3.7
1.8
2.7
14.7
4.2
3.9
0.5
3.2
0.2
1.7
5.2
1.5
0
0
0
0
0

income-statement-row.row.interest-expense

0031200.6423.8
170.5
101.3
0
0
0
24.5
30.6
30.4
28.7
21.6
25.8
23.3
32.1
21
16.1
14.3
13.9
15.5
10.7
8.5
8.3
-0.4
-0.6
0.3
1.4
0.3

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

0-1868-30964.1-32573.9
-2432.1
-8419.3
-18306.3
-4428.3
-1585.5
390.9
203.2
-45.4
52.4
-58.5
23.6
13.6
-7.9
58.1
13.2
-14.4
0.5
-9.5
-9.1
-0.2
-3.1
6.1
12.8
6.6
10.1
6.2

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

0-48509.69825.59896.8
36146.5
30062.1
-24280.3
-23688.3
-6190.4
3.1
8.3
13.2
1.5
0.3
9.8
6
5
6
10.3
4.7
9.5
1.5
2.6
8.3
7.3
20.6
11.9
5.6
6.6
2

income-statement-row.row.total-operating-expenses

0-1868-30964.1-32573.9
-2432.1
-8419.3
-18306.3
-4428.3
-1585.5
390.9
203.2
-45.4
52.4
-58.5
23.6
13.6
-7.9
58.1
13.2
-14.4
0.5
-9.5
-9.1
-0.2
-3.1
6.1
12.8
6.6
10.1
6.2

income-statement-row.row.interest-expense

0031200.6423.8
170.5
101.3
0
0
0
24.5
30.6
30.4
28.7
21.6
25.8
23.3
32.1
21
16.1
14.3
13.9
15.5
10.7
8.5
8.3
-0.4
-0.6
0.3
1.4
0.3

income-statement-row.row.depreciation-and-amortization

01840.9147.3133.9
63.7
79.2
1123.9
122.9
139.3
64.8
73.5
68.8
52.4
62.9
66.5
52.3
40.5
42
35.6
37.6
35.9
34.2
37.3
28.9
28.6
25.1
13.1
-11.9
-13.4
-8.3

income-statement-row.row.ebitda-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

01216.331188.832917
3881.5
12052.8
2653.6
2727.4
3424.8
332.2
101.1
-141.1
14.9
-113.7
22.2
53.2
2.3
106.4
53.1
8.2
-1.7
-45.1
15.8
57.5
48.3
41.8
30.7
63.1
48.6
30.8

income-statement-row.row.income-before-tax

0-1868224.8343.1
1449.5
3633.4
2636.4
2724.3
3432.6
334.4
109
-128.6
15
-116.7
31.1
59.2
7.3
112.4
57.9
8.4
5
-47.3
16.2
57.7
48.9
47.6
39.7
63.3
50.3
30.8

income-statement-row.row.income-tax-expense

0-1216.3-285.8-537.1
331.6
714.9
259.1
46
323.7
83.9
24.8
-28.1
1.2
-9.5
2
3.9
-0.1
20.5
4.8
0.3
0.1
1.7
8.3
11
8.5
12.2
9.2
8.5
13.4
8

income-statement-row.row.net-income

0-651.8510.6880.2
1117.9
2918.6
1326.5
1326.2
1778.7
247.3
83.8
-101
11.8
-101.7
28.3
55.8
-23.8
89.7
48.4
7.1
5.1
-48.1
5.3
37.2
34.2
31.3
30.2
54.8
36.9
22.8
Panašios akcijos
Jus taip pat gali dominti:
0JV3.L
Lincoln National Corporation.
29.55 USD
LSE
AAME
Atlantic American Corporation.
1.8656 USD
NASDAQ
0966.HK
China Taiping Insurance Holdings Company Limited.
7.96 HKD
HKSE
MET
MetLife, Inc..
72.54 USD
NYSE
PUKPF
Prudential plc.
8.8 USD
PNK
JPPIF
Japan Post Insurance Co., Ltd..
18.5 USD
PNK
MGDL.TA
Migdal Insurance and Financial Holdings Ltd..
485 ILA
TLV
MET-PA
MetLife, Inc..
24.4514 USD
NYSE
PRU.L
Prudential plc.
787.8 GBp
LSE
JMAS.JK
PT Asuransi Jiwa Syariah Jasa Mitra Abadi Tbk.
54 IDR
JKT
0376.HK
Yunfeng Financial Group Limited.
0.78 HKD
HKSE

Dažnai užduodami klausimai

Kas yra Hubei Biocause Pharmaceutical Co., Ltd. (000627.SZ) bendras turtas?

Hubei Biocause Pharmaceutical Co., Ltd. (000627.SZ) bendras turtas yra 301935930342.000.

Kokios yra įmonės metinės pajamos?

Metinės pajamos yra N/A.

Kokia yra įmonės pelno marža?

Įmonės pelno marža yra 0.698.

Koks yra įmonės laisvųjų pinigų srautas?

Laisvųjų pinigų srautas yra -2.454.

Kokia yra įmonės grynojo pelno marža?

Grynojo pelno marža yra -0.007.

Kokios yra bendros įmonės pajamos?

Bendrosios pajamos yra 0.006.

Kas yra Hubei Biocause Pharmaceutical Co., Ltd. (000627.SZ) grynasis pelnas (grynosios pajamos)?

Grynasis pelnas (grynosios pajamos) yra -651784800.000.

Kokia yra bendra įmonės skola?

Bendra skola yra 25418877126.000.

Koks yra veiklos sąnaudų skaičius?

Veiklos sąnaudos yra -48509569700.000.

Koks yra įmonės grynųjų pinigų skaičius?

Įmonės grynieji pinigai yra 0.000.